Press release Oncology Venture acquires full ownership of its PARP inhibitor (2X-121) program

NEXT STORY
Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
PREV STORY
TRACON Pharmaceuticals to Host Key Opinion Leader Webinar on Envafolimab for the Treatment of Sarcoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science

author_avatar
NASDAQ Market News

United States In Vitro Diagnostics Tests Market Report 2021-2025 – It is Realistic to Assume the Market for COVID-19 will Remain a Component of the IVD Market

author_avatar
NASDAQ Market News

Conformis, Inc. Announces Clearance in Australia for iTotal® PS, the Only Personalized, Posterior-Stabilized Total Knee Replacement System

author_avatar
NASDAQ Market News